Caribou Biosciences, Inc. to Post Q1 2023 Earnings of ($0.49) Per Share, HC Wainwright Forecasts (NASDAQ:CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBU – Get Rating) – Equities research analysts at HC Wainwright upped their Q1 2023 earnings per share estimates for Caribou Biosciences in a report issued on Tuesday, March 14th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.49) per share for the quarter, up from their prior estimate of ($0.50). HC Wainwright has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($2.00) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q2 2023 earnings at ($0.51) EPS, Q3 2023 earnings at ($0.53) EPS, Q4 2023 earnings at ($0.55) EPS and FY2023 earnings at ($2.08) EPS.

Several other analysts also recently commented on CRBU. Oppenheimer dropped their target price on shares of Caribou Biosciences from $36.00 to $32.00 and set an “outperform” rating on the stock in a report on Friday, March 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $19.00 target price on shares of Caribou Biosciences in a report on Friday, March 10th. Finally, Citigroup cut their price objective on Caribou Biosciences from $38.00 to $37.00 in a research report on Wednesday, November 23rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Caribou Biosciences has a consensus rating of “Buy” and a consensus target price of $29.60.

Caribou Biosciences Stock Down 2.3 %

Shares of NASDAQ CRBU opened at $5.04 on Thursday. Caribou Biosciences has a twelve month low of $4.89 and a twelve month high of $13.19. The stock has a market cap of $308.95 million, a price-to-earnings ratio of -3.07 and a beta of 1.93. The company’s fifty day moving average is $6.53 and its 200-day moving average is $8.34.

Institutional Trading of Caribou Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. International Biotechnology Trust PLC purchased a new position in shares of Caribou Biosciences in the second quarter worth about $255,000. Ameritas Investment Partners Inc. raised its position in shares of Caribou Biosciences by 168.4% in the first quarter. Ameritas Investment Partners Inc. now owns 3,945 shares of the company’s stock worth $36,000 after buying an additional 2,475 shares in the last quarter. Penserra Capital Management LLC bought a new stake in shares of Caribou Biosciences during the 1st quarter valued at about $61,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Caribou Biosciences during the second quarter valued at approximately $57,000. Finally, E Fund Management Co. Ltd. bought a new position in shares of Caribou Biosciences in the 4th quarter worth $70,000. 70.44% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Caribou Biosciences

In related news, insider Syed Ali-Aamir Rizvi sold 5,627 shares of Caribou Biosciences stock in a transaction that occurred on Thursday, January 19th. The stock was sold at an average price of $6.31, for a total value of $35,506.37. Following the transaction, the insider now directly owns 59,373 shares of the company’s stock, valued at $374,643.63. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.50% of the stock is owned by insiders.

About Caribou Biosciences

(Get Rating)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma.